1168 results about "Divalent metal" patented technology

A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II) together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; and at least one pharmaceutical excipient; said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II). A crystalline salt of formula (II) and a process for preparing said salt.

Novel two-phase yellow phosphors are disclosed having a peak emission intensity at wavelengths ranging from about 555 nm to about 580 nm when excited by a radiation source having a wavelength ranging from 220 nm to 530 nm. The present phosphors may be represented by the formula a[Srx(M1)1-x]zSiO4●(1-a)[Sry(M2)1-y]uSiO5:Eu2+D, wherein M1 and M2 are at least one of a divalent metal such as Ba, Mg, Ca, and Zn, the values of a, x, y, z and u follow the following relationships: 0.6≦a≦0.85; 0.3≦x≦0.6; 0.85≦y≦1; 1.5≦z≦2.5; 2.6≦u≦3.3; and Eu and D each range from 0.001 to about 0.5. D is an anion selected from the group consisting of F, Cl, Br, S, and N, and at least some of the D anion replaces oxygen in the host silicate lattice of the phosphor. The present yellow phosphors have applications in high brightness white LED illumination systems, LCD display panels, plasma display panels, and yellow LEDs and illumination systems.

The invention provides an optoelectronic device comprising a mixed-anion perovskite, wherein the mixed-anion perovskite comprises two or more different anions selected from halide anions and chalcogenide anions. The invention further provides a mixed halide perovskite of the formula (I) [A][B][X]3 wherein: [A] is at least one organic cation; [B] is at least one divalent metal cation; and [X] is said two or more different halide anions. In another aspect, the invention provides the use of a mixed-anion perovskite as a sensitizer in an optoelectronic device, wherein the mixed-anion perovskite comprises two or more different anions selected from halide anions and chalcogenide anions. The invention also provides a photosensitizing material for an optoelectronic device comprising a mixed-anion perovskite wherein the mixed-anion perovskite comprises two or more different anions selected from halide anions and chalcogenide anions.

The present invention provides a comprehensive solution to skin problems of infants and incontinent adults related to diaper rash, also known as diaper dermatitis. This is based on certain novel divalent metal and quaternary ammonium complexes (ion-pairs) of zeolites (that are made by an in-situ process), which in synergistic combination with certain other compositions, provide a comprehensive treatment for diaper rash that encompasses the following aspects: (1) deactivation of lipase and protease enzymes on skin surface, (2) the controlled-release delivery of skin protectant compositions, such as divalent metal zinc cation, (3) trapping of acidic and alkaline chemicals deposited on skin from body exudates and enzyme activity, (4) controlled-release delivery of anti-inflammatory agents, and COX and LOX enzyme inhibitors, (5) controlled-release delivery of antibacterial and antifungal compositions, and (6) absorption of excess moisture in the diaper zone.

Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.

Novel two-phase yellow phosphors are disclosed having a peak emission intensity at wavelengths ranging from about 555 nm to about 580 nm when excited by a radiation source having a wavelength ranging from 220 nm to 530 nm. The present phosphors may be represented by the formula a[Srx(M1)1−x]zSiO4.(1-a)[Sry(M2)1−y]uSiO5:Eu2+D, wherein M1 and M2 are at least one of a divalent metal such as Ba, Mg, Ca, and Zn, the values of a, x, y, z and u follow the following relationships: 0.6≦a≦0.85; 0.3≦x≦0.6; 0.85≦y≦1; 1.5≦z≦2.5; 2.6≦u≦3.3; and Eu and D each range from 0.001 to about 0.5. D is an anion selected from the group consisting of F, Cl, Br, S, and N, and at least some of the D anion replaces oxygen in the host silicate lattice of the phosphor. The present yellow phosphors have applications in high brightness white LED illumination systems, LCD display panels, plasma display panels, and yellow LEDs and illumination systems.

The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.

The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.

A phosphor (A) comprising a host material composed of a compound having a garnet crystal structure represented by the general formula (I):M1aM2bM3cOd  (I)(wherein M1 is a divalent metal element, M2 is a trivalent metal element, M3 is a tetravalent metal element containing at least Si, a is the number of 2.7 to 3.3, b is the number of 1.8 to 2.2, c is the number of 2.7 to 3.3, and d is the number of 11.0 to 13.0), and a luminescent center ion incorporated in the host material; a light emitting device (B) comprising the phosphor as a wavelength conversion material and a semiconductor light emitting element capable of emitting a light in the range of from ultraviolet light to visible light; and a display (C) and a lighting system (D) using the light emitting device (B) as a light source. The above phosphor can be readily produced, and can provide a light emitting device having a high color rendering property.

The disclosure relates to asymmetric supercapacitors containing: a positive electrode comprising a current collector and a first active material selected from a layered double hydroxide of formula [M2+1−xMx3+(OH)2]An−x / n·mH2O where M2+ is at least one divalent metal, M3+ is at least one trivalent metal and A is an anion of charge n−, where x is greater than zero and less than 1, n is 1, 2, 3 or 4 and m is 0 to 10; LiCoO2; LiCoxNiyO2 where x and y are greater than zero and less than 1; LiCoxNiyMn(1−x−y)O2 where x and y are greater than zero and less than 1; CoSx where x is from 1 to 1.5; MoS; Zn; activated carbon and graphite; a negative electrode containing a material selected from a carbonaceous active material, MoO3 and Li1xMoO6−x / 2; an aqueous electrolyte solution or a non-aqueous ionic conducting electrolyte solution containing a salt and a salt and a non-aqueous solution; and a separator plate. Alternatively, the electrolyte can be a solid electrolyte.

A stable solid pharmaceutical composition consisting essentially of an effective amount of a salt of formula (II)together with an alkaline-reacting component maintaining the pH preferably above 8, or a salt with a divalent metal cation; andat least one pharmaceutical excipient;said salt of formula (II) being essentially stable during storage at room temperature for a period of at least 3 years. A process for stabilizing the salt of formula (II).A crystalline salt of formula (II) and a process for preparing said salt.

A composition is provided, which comprises a water-soluble salt of a divalent metal; a complexing agent having an affinity for the divalent metal; and an optical brightening agent. Methods of using the composition, and recording sheets which include the composition, are also disclosed.

Novel phosphor systems are disclosed having the formula A2SiO4:Eu2+D, where A is at least one of a divalent metal selected from the group consisting of Sr, Ca, Ba, Mg, Zn, and Cd; and D is a dopant selected from the group consisting of F, Cl, Br, I, S and N. In one embodiment, the novel phosphor has the formula (Sr1-x-yBaxMy)2SiO4: Eu2+F (where M is one of Ca, Mg, Zn, or Cd in an amount ranging from 0<y<0.5). The phosphor is configured to absorb visible light from a blue LED, and luminescent light from the phosphor plus light from the blue LED may be combined to form white light. The novel phosphors can emit light at intensities greater than either conventionally known YAG compounds, or silicate-based phosphors that do not contain the inventive dopant ion.

A phosphor which emits light having high brightness, serves as an excellent orange or red phosphor whose light brightness is less decreased when exposed to an excitation source contains a crystal phase having the chemical composition expressed by the general formula [1]:(1−a−b)(Ln′pMII′1−pMIII′MIV′N3)·a(MIV′(3n+2) / 4NnO)·b(AMIV′2N3)  [1]wherein Ln′ represents a metal element selected from the group consisting of lanthanoids, Mn, and Ti; MnII′ represents a divalent metal element except the Ln′ element; MIII′ represents a trivalent metal element; MIV′ represents a tetravalent metal element; A represents a metal element selected from the group consisting of Li, Na, and K; 0<p≦0.2; 0≦a, 0≦b, a+b>0, 0≦n, and 0.002≦(3n+2)a / 4≦0.9.

Disclosed are an organic domain / inorganic domain hybrid material comprising an organic domain comprising at least one water-soluble organic polymer having anionic and / or cationic functional groups, and an inorganic domain, the organic and inorganic domains being chemically bonded to each other through the functional groups, the inorganic domain comprising inorganic bridges, each independently comprising at least one Si atom, at least two O atoms and at least one divalent metal atom, wherein the Si atom and the O atoms together form at least one siloxane linkage arranged longitudinally of the inorganic bridge, wherein each divalent metal atom is ionically bonded to the O atoms of the siloxane linkages positioned adjacent to the divalent metal atoms, wherein, when at least a part of the organic domain is comprised of at least one organic polymer having an anionic functional group and optionally a cationic functional group, the organic domain / inorganic domain weight ratio is less than 1.0; and the use thereof as a hydrophilicity reagent and an antibacterial / antifungal reagent.

The instant invention relates to liquid compositions comprising derivatives of diaminostilbene, binders and ink fixing agents such as divalent metal salts for the optical brightening of substrates suitable for high quality ink jet printing.

The present invention provides sustained release compositions that can be manufactured easily while providing long duration of the pharmaceutically useful protein being delivered. The compositions comprise insoluble complexes of the pharmaceutically useful protein and a precipitating agent at an appropriate ratio to achieve a desired sustained release profile. The precipitating agent can be selected from a group of various agents including divalent metal cations, Hofmeister series salts and pH adjusters. Particularly provided are compositions comprising insulin that are suitable for pulmonary delivery.

The invention provides a novel thermal insulation coating material with no phase transfer problem, a melting point higher than the working temperature range, a thermal conductivity lower than that of zirconia, and a thermal expansion rate higher than that of zirconia. The thermal barrier coating material has an orthorhombic or monoclinic crystal structure derived from perovskite (for example, a platy perovskite structure represented by the composition formula A2B2O7), or a c-axis / a-axis ratio of 3 or more The composition of the tetragonal layered structure (such as K2NiF4 structure and Sr3Ti2O7 structure, Sr4Ti3O10 structure), and the composition represented by the composition formula LaTaO4, and the composition with the composition formula M2SiO4 or (MM') 2SiO4 (wherein M, M 'is a divalent metal element) composition of the olivine structure represented as the main body.

The present disclosure describes the broadly active chelation of diverse divalent 2+ metal cations by any oligonucleotide (ON), regardless of size or modification. This chelation effect is specific to cations which are divalent (or of higher valency) and results in the formation of oligonucleotide chelate complexes which do not behave like salts. It is described herein a novel composition of an ON chelate complex prepared using any ON and a divalent metal cation and methods for the suppression of anti-coagulation and or subcutaneous injection site reactions and or improved tolerability with oligonucleotides by the use of ON chelate complexes during oligonucleotide administration.

Anti-odor and anti-plaque compositions for oral use are provided comprising an anti-odor and anti-plaque active component of an extract of Glycyrrhiza glabra or Usnea spp., an anti-odor or anti-plaque active component of such extracts, and mixtures thereof. The composition may further comprise a cationic and / or non-ionic surfactant, divalent metal cations, oligosaccharides, suitable solubilizing carriers and other additives.

The invention discloses a P-type doped perovskite-based photoelectric functional material, prepared by taking a perovskite-based photoelectric functional material ABX3 as a substrate and organic or inorganic doping agent as a P-type doping agent for doping purpose. The chemical formula of the obtained perovskite-based photoelectric functional material is (A1)<x>(A2)<1-x>B(X1)<y>(X2)<3-y>, wherein 0<=x<=1, 0<=y<=3, A1 is a monovalent organic or inorganic cation, A2 is a monovalent organic or inorganic cation, B is a divalent metal cation, and X1 or X2 is a monovalent anion. The invention further discloses a corresponding preparation method and a solar cell and the like comprising the photoelectric functional material. The P-type doped perovskite-based photoelectric functional material has the advantages that carrier concentration, hole mobility and conductivity can be improved; the perovskite-based photoelectric functional material with excellent electrical property can be obtained; and the preparation method is simple and low in cost.

The invention relates to a method for hydrothermally preparing mono-dispersed hollow magnetic nanometer particles. The method comprises the following steps of: firstly, mixing a divalent metal salt solution with a urea solution; secondly, adding an organic dispersant and a divalent metal oxidation inhibitor; thirdly, slowly adding an alkali precipitant solution into the solution; fourthly, adjusting the pH (Potential of Hydrogen) value of the mixed solution to 10-12; and finally, adding a surface radical modifier, and carrying out hydrothermal reaction for 5-15 hours at the temperature of 150-250 DEG C, so as to prepare the magnetic nanometer particles having a hollow structure. Compared with the prior art, the method provided by the invention has the advantages of simple technique step, low cost and the like, and is easy to be large-scale.

A method of decontaminating soil and ground water containing organic contaminants and divalent metal compounds. It comprises the steps of first treating such soils and ground water with an effective amount an aqueous solution containing a peroxide and a water soluble chelating agent for a time sufficient to have the water soluble chelating agent chelate at least one of the divalent metals of the divalent metal compounds present in the soil and ground water. Next, the chelated metals are brought into contact with the peroxide to catalytically convert the peroxide to an oxidizing agent. Finally, the last step is contacting the organic contaminants in the soil and ground water with the oxidizing agent to oxidize the organic contaminants to environmentally safe, non-toxic compounds.

Aqueous dispersions comprising microfine metal oxide particles and dispersion auxiliaries, wherein, as dispersion auxiliaries, at least one of the compounds of the general formula (I)in whichM is hydrogen, monovalent or divalent metal cation, ammonium ion, organic amine radical;a is 1, or where M is a divalent metal cation, is ½;X is likewise —OMa or —O—(CpH2pO)q—Rl where R1═H, aliphatic hydrocarbon radical having 1-20 carbon atoms, cycloaliphatic hydrocarbon radical having 5 to 8 carbon atoms, optionally substituted aryl radical having 6 to 14 carbon atoms, p=2 to 4, q=0 to 100, —NHR2 and / or —NR22 where R2═R1 or —CO—NH2;Y is O, NR2;A1 is ethylene radical, propylene radical, isopropylene radical, butylene radical;m is 10 to 30;n is 0 to 50; andk is 10 to 30, where the summ+k is in the range from 20 to 60, is co-used.

The present invention relates to insoluble compositions comprising a protein selected from the group consisting of insulin, insulin analogs, and proinsulins; a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; a complexing compound; a hexamer-stabilizing compound; and a divalent metal cation. Formulations of the insoluble composition are suitable for both parenteral and non-parenteral delivery for treating hyperglycemia and diabetes. Microcrystal forms of the insoluble precipitate are pharmaceutically analogous to the neutral protamine Hagedorn (NPH) insulin crystal form. Surprisingly, it has been discovered that suspension formulations of such insoluble compositions possess unique and controllable dissolution properties that provide therapeutically advantageous glucodynamics compared with insulin NPH formulations.

The invention relates to chemically tempered antimicrobial boroaluminosilicate glass free of color change. The boroaluminosilicate glass is characterized in that the content of B2O3 can meet the following relational expression as shown in the specification, wherein M2O is the sum of content of all monovalent metal oxides in the glass; MO is the sum of content of all divalent metal oxides in the glass; RO is the sum of all multivalent element oxides with potential reducing capacity in the glass; all content in the formula is based on mole percents of oxides; and the content of RO is based on the mole percents of the oxide with the highest cation valence. The glass can be tempered in a salt bath containing 0-5wt% of silver nitrate, so that high strength and excellent antibacterial property are obtained in one step; and high transmittance and colorless features are kept. The glass can be used as protecting glass of touch screens of mobile phones or other electronic equipment, can also be used as surfaces of any high-strength, scratch-resistant, transparent and antimicrobial equipment and apparatuses, which are frequently touched by people in hospitals and communal facilities, or even the surfaces of buildings.

The invention relates to a Fischer-Tropsch synthesis catalyst, its preparation and application. The catalyst contains a carrier and an active metal component that is loaded on the carrier and is selected from iron and / or cobalt. The catalyst is characterized in that, the carrier is a surface modified porous heatproof inorganic oxide molded carrier composed of silicon and one or more divalent metal components selected from the IIA group, the VIII group, the IB group and the IIB group. In terms of elements and based on the carrier, the content of silicon is 0.3-3.5 wt%, and the content of the divalent metal components is 0.2-2.0 wt%. Compared with the prior art, the catalyst provided in the invention has high wear resistance, and also has high activity and selectivity at the same time.

The invention discloses a five-element transition metal oxide high-entropy material for a lithium-ion battery. The high-entropy material is a five-element spinel type oxide high-entropy material formed by five transition metal positive ions, the chemical formula of the high-entropy material is (Cr0.2Fe0.2Mn0.2Zn0.2M0.2)3O4, wherein M is a divalent metal positive ion Co2+ or Ni2+. According to theinvention, a high-entropy oxide material with a spinel structure and different chemical compositions is regulated and controlled by changing the variety of divalent transition metal positive ions, sothat the electrochemical performance of the high-entropy oxide material is customized, and a nanocrystalline powder material with large specific surface area, small grain size and uniform chemical composition and microstructure is prepared through a combustion synthesis method. The five-element transition metal oxide high-entropy material for the lithium-ion battery has the advantages of large initial charge specific capacity, stable reversible specific capacity, good rate capability and good cycling stability.

The present invention provides a glass composition that exhibits a fluorescence function and an optical amplification function in a wide wavelength range. This glass composition includes a bismuth oxide, a silicon oxide, an aluminum oxide, and a divalent metal oxide, and the glass composition emits fluorescence in an infrared wavelength region through irradiation of excitation light, with bismuth contained in the bismuth oxide functioning as a fluorescent source.